Advances in pharmacological interventions for hepatic fibrosis: from pathogenic mechanisms to novel therapeutic targets

Hepatic fibrosis (HF) is a pahological consequence of dysregulated wound healing, characterized by excessive deposition of extracellular matrix (ECM) that disrupts liver architecture and function.It is driven by diverse etiologies, including viral, metabolic, cholestatic and toxic insults. Additionally, the pathogenetic mechanisms progressing from initial injury to established fibrosis involve hepatocyte dysfunction, impaired autophagy, oxidative stress, immune modulation, and ultimately the activation of hepatic stellate cells, leading to a sustained imbalance between ECM synthesis and degradation. Consequently, developing effective therapies necessitates strategies targeting both specific etiologies and…

• NN
  National Natural Science Foundation of China

  Award: 82370660, 82000612
• BA
  Basic and Applied Basic Research Foundation of Guangdong Province

  Award: 2024A1515012631, 2024A1515012847